Randomized, controlled trial of thel effect of luseogliflozin in type 2 diabetic patients with fattiy liver

Randomized, controlled trial of thel effect of luseogliflozin in type 2 diabetic patients with fattiy liver - Randomized, controlled trial of thel effect of luseogliflozin in type 2 diabetic patients with fattiy liver

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016090

Enrollment

Registered

2015-02-01

Start date

2015-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetic patients with fatty liver

Interventions

luseogliflozin metformin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.patient with type 2 diabetes 2.patient diagnosed fatty liver by abdominal sonography

Exclusion criteria

Exclusion criteria: 1.patients with renal failure 2.patients who have had cerebral infarction 3.patients who have had myocardial infarction 4.patients who is administered diuretics 5.patients who have dehydration 6.patient who is inadequate for this trial

Design outcomes

Primary

Measure	Time frame
A liver attenuation index at unen- hanced CT 24 week after administration	—

Secondary

Measure	Time frame
liver enzyme, fasting plasma glucose ,and HbA1c 24week after administration	—

Countries

Japan

Contacts

Public ContactTakashi Shibuya

Ichinomiyanishi hospital Department of Endocrinology and Diabetes

shibuyan@csc.jp0586-48-0077

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026